Federated Hermes, Inc. Halozyme Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 711,808 shares of HALO stock, worth $33.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

711,808

Previous 696,131 2.25%

Holding current value

$33.8 Million

Previous $36.4 Million 11.72%

% of portfolio

0.09%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $804,230 - $1.01 Million	15,677 Added 2.25%	711,808 $40.7 Million
Q2 2024 Aug 08, 2024	BUY	$37.81 - $52.4 $7.22 Million - $10 Million	191,030 Added 37.82%	696,131 $36.4 Million
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $1.54 Million - $1.92 Million	45,732 Added 9.96%	505,101 $20.5 Million
Q4 2023 Jan 31, 2024	BUY	$33.32 - $42.1 $9.76 Million - $12.3 Million	292,926 Added 175.99%	459,369 $17 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $4.15 Million - $5.01 Million	113,760 Added 215.93%	166,443 $6.36 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $285,116 - $364,775	9,416 Added 21.76%	52,683 $1.9 Million
Q1 2023 May 08, 2023	SELL	$32.86 - $55.7 $719,929 - $1.22 Million	-21,909 Reduced 33.62%	43,267 $1.65 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $347,119 - $515,047	-8,665 Reduced 11.73%	65,176 $3.71 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $373,972 - $502,576	-9,706 Reduced 11.62%	73,841 $2.92 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $97,632 - $126,256	-2,614 Reduced 3.03%	83,547 $3.68 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $3.9 Million - $5 Million	-121,862 Reduced 58.58%	86,161 $3.44 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $3.62 Million - $4.63 Million	-113,693 Reduced 35.34%	208,023 $8.36 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $3.4 Million - $4.11 Million	88,438 Added 37.91%	321,716 $13.1 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $5.93 Million - $7.83 Million	-152,659 Reduced 39.56%	233,278 $10.6 Million
Q1 2021 May 13, 2021	BUY	$39.51 - $51.45 $5.53 Million - $7.21 Million	140,064 Added 56.97%	385,937 $16.1 Million
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $4.65 Million - $7.85 Million	-180,047 Reduced 42.27%	245,873 $10.5 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $86,126 - $99,141	-3,346 Reduced 0.78%	425,920 $11.2 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $6.01 Million - $9.91 Million	369,599 Added 619.44%	429,266 $11.5 Million
Q1 2020 May 13, 2020	SELL	$13.9 - $21.83 $3.55 Million - $5.58 Million	-255,540 Reduced 81.07%	59,667 $1.07 Million
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $3.24 Million - $4.24 Million	-217,310 Reduced 40.81%	315,207 $5.59 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $4.4 Million - $5.12 Million	-289,266 Reduced 35.2%	532,517 $8.26 Million
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $154,285 - $180,539	-10,460 Reduced 1.26%	821,783 $14.1 Million
Q1 2019 May 10, 2019	BUY	$13.94 - $17.58 $2.91 Million - $3.67 Million	209,033 Added 33.54%	832,243 $13.4 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $6.06 Million - $8.48 Million	454,383 Added 269.14%	623,210 $9.12 Million
Q3 2018 Nov 13, 2018	BUY	$16.68 - $18.41 $1.05 Million - $1.16 Million	63,015 Added 59.55%	168,827 $3.07 Million
Q2 2018 Aug 10, 2018	SELL	$16.87 - $20.3 $1.22 Million - $1.47 Million	-72,318 Reduced 40.6%	105,812 $1.79 Million
Q1 2018 May 09, 2018	BUY	$17.06 - $21.2 $1.5 Million - $1.86 Million	87,709 Added 97.0%	178,130 $3.49 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $595,596 - $739,606	35,558 Added 64.81%	90,421 $0
Q3 2017 Nov 13, 2017	BUY	$11.76 - $17.4 $645,188 - $954,616	54,863	54,863 $953,000

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Halozyme Therapeutics, Inc. Transaction History